In recent months Proteon has completed a Phase II study for its lead vessel-dilating candidate PRT-201, advancing the program to where Novartis can take its four-year-old option to gobble up the biotech outfit entirely.
Closing in on the selection of its lead cancer program, San Francisco-based Cleave Biosciences has welcomed the deep-pocketed player New Enterprise Associates to its list of venture backers and topped up its Series A with a $10 million investment in its early-stage drug research work.
In another sign that gene therapy has come of age, Paris-based GenSight Biologics is lifting off with a $41 million shot in the arm from a lineup of blue chip VCs, led by a Big Pharma venture arm--Novartis Venture Fund--along with Abingworth, Versant Ventures and Index Ventures.
San Diego-based biotech Receptos has taken steps to mount an initial public offering, filing papers with the SEC to raise up to $86.3 million in the deal.
They are already rich, so why spotlight billionaires like Microsoft Chairman Bill Gates and Teva Chairman Dr. Phillip Frost ? Well, the mega-wealthy have made an impact all over the biopharma world,...
Taris Biomedical has gone back to the venture well as the biotech startup launches a midstage study of its lead candidate against bladder pain. The Lexington, MA-based company found support for its latest financing from previous backers at Flybridge Capital Partners, Flagship Ventures, Polaris Venture Partners and Third Rock Ventures.
The venture arms for Johnson & Johnson and Pfizer have helped spearhead an $18 million investment round for Canada's Aquinox Pharmaceuticals as the biotech plots the next big step in a mid-stage program for its lead anti-inflammatory drug.
A low-profile biotech based in San Jose, CA, has managed to piece together a $12 million round from dozens of angel investors willing to back its work on a new schizophrenia treatment. Reviva Pharmaceuticals filed a Series D with the SEC recently detailing a contribution of $12,039,776.65 from 82 investors backing its mid-stage program, which is due to deliver data any day now.
A lengthy slate of venture backers added $8 million to the round, bringing the total raised so far to $50 million.
Ex-BlackBerry chief and co-founder Mike Lazaridis has given life to a $97 million fund to advance quantum technology, which has major implications for computing, medicine and other fields.